Article By:
ChinaBio® Today
Saturday, October 20, 2018 4:16 PM EDT
Innovent Biologics of Suzhou plans to raise $422 million in its Hong Kong IPO at a $2 billion valuation, according to multiple media reports. The company, formed in 2011, struck a major $1 billion collaboration with Lilly in 2015.